Full Breakdown
NTU Takes Position on Four Senate Health Bills Ahead of July 22, 2026 Markup
7/23/2026, 6:24:48 AM
Core Event
On the scheduled July 22, 2026 markup before the Senate Committee on Health, Education, Labor and Pensions, the National Taxpayers Union submitted written comments on four pending bills. NTU endorsed S. 1414, the Expedited Access to Biosimilars Act, and opposed S. 4189, the INSULIN Act of 2026, as well as S. 5026, the Childhood Diabetes Reduction Act.
Background & Context
The Senate committee is reviewing a broader health-care package that includes measures aimed at drug pricing, biosimilar competition, and nutrition labeling. NTU frames its analysis through a free-market lens, arguing that taxpayer interests are best served by reducing regulatory barriers rather than imposing price caps or new labeling mandates.
Official Statements & Responses
- Support for S. 1414 – NTU praised the bill, authored by Sen. Paul (R-KY), for streamlining the Food and Drug Administration’s approval process for biosimilar drugs. The organization noted that current requirements force manufacturers to conduct costly clinical studies even when safety and efficacy are already demonstrated, and that greater competition typically drives down prices in taxpayer-funded programs.
- Opposition to S. 4189 – Authored by Sen. Shaheen (D-NH), the INSULIN Act would cap monthly insulin costs at $35 for insured patients and create a pilot program for the uninsured. NTU argued that price caps shift costs to insurers, likely resulting in higher premiums for consumers, and that such mandates do not eliminate overall spending.
- Opposition to S. 5026 – Sponsored by Sen. Sanders (I-VT), the Childhood Diabetes Reduction Act would require new warning labels on foods high in sugar, sodium, saturated fats, artificial sweeteners, or other “ultra-processed” ingredients and restrict advertising to children. NTU contended that existing FDA labeling rules already provide extensive disclosure, that the bill would add compliance costs passed to consumers, expand federal bureaucracy, and raise free-speech concerns.
Why It Matters
NTU’s positions highlight a policy divide between market-based reforms that aim to increase drug competition and regulatory approaches that impose price or labeling controls. The outcomes of the markup could shape how future legislation balances taxpayer cost savings with industry regulation in the U.S. health-care system.
